Celsion Reports Updated Survival Data In ThermoDox Study Of Liver Cancer

(RTTNews) - Celsion Corp. (CLSN) Monday announced its latest updated results from its retrospective analysis of 701-patient -HEAT Study of ThermoDox in combination with radiofrequency ablation or RFA in primary liver cancer or hepatocellular carcinoma. The latest quarterly Overall Survival or OS analysis showed that 285 Patient Subgroup or 41 percent of the study patients who were treated with the combination of ThermoDox and optimized RFA provided a 57 percent improvement in overall survival compared with optimized RFA alone. The company said the fifth and the final data set demonstrates a statistically significant survival benefit. However, the company noted that the data and supporting analysis from the HEAT Study warrant additional clinical development and the information should be viewed with caution since it is based upon a retrospective analysis and this subgroup of the HEAT Study has not reached its median point for OS analysis.